MedTrace Logo

A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China

NCT07450170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3485

Last updated 2026-04-15

No results posted yet for this study

Summary

The aim of this study was to characterize the real-world treatment patterns of omalizumab among adult patients with chronic urticaria in China using data from a regional electronic healthcare (rEHR) database. This included assessing the frequency and proportion of prescriptions across different dosages of omalizumab in real-world clinical practice.

Conditions

  • Chronic Urticaria

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2026-03-23
Completion
2026-03-23

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07450170 on ClinicalTrials.gov